

## **ID926 Strimvelis ERG report errata**

The amended pages are in the accompanying document 'ID926 Strimvelis ERG report post FAC amended pages'

### *Section 4.2.5, p46*

A similar subgroup analyses by decade for HSCT from a MUD was not available from that dataset which particularly limits the comparison between this treatment and Strimvelis.

### *Section 4.2.5, p47*

In response to an ERG request for clarification, the company stated that two patients had contaminated drug product (one of these received back up bone marrow as a result of this). Of the three patients who received cells due to an event after Strimvelis treatment, one patient received back up bone marrow and two patients received their CD34 negative fraction. [REDACTED]

### *Section 4.2.6, p48*

The company submission reported that 11 Strimvelis patients had discontinued IVIG during follow up (8 before 3 years follow up and 3 after 3 years follow up).

### *Section 4.3, p54*

In addition, as pointed out by our clinical advisor, there has been evidence<sup>1</sup> of silencing of gene expression in patients with chronic granulomatous disease (CGD) following gene therapy. Gene silencing can result in a loss of therapeutic benefit but further study is required to assess the risks in ADA-SCID patients.

### *Section 5.2.3, p73*

The Strimvelis Integrated Population are older (mean 2.1 years at gene therapy), more frequently male (61%) and a proportion had already undertaken a HSCT prior to gene therapy (22.2%) or received PEG-ADA (83% PEG-ADA of any duration; 72.2% PEG-ADA of duration >3 months).

### *Section 5.2.6.2, p78*

The source used to inform survival after HSCT is a retrospective survey of 16 international transplant centres, which included 44/106 (41.5%) HSCTs provided in the UK.

### *Table 9, p81*

**Table 1: Summary of primary efficacy data reported by the company**

	Success, long term	Unsuccessful engraftment, PEG-ADA, awaiting	Death	Source
--	--------------------	---	-------	--------

<sup>1</sup> Qasim W, Gennery AR. Gene therapy for primary immunodeficiencies: current status and future prospects. *Drugs* 2014; 74:963-969.

	survival	rescue transplant		
Strimvelis	14/17 (82.4%)	3/17 (17.6%)	0/17 (0%)	Strimvelis long-term integrated population study
MUD	9/15 (60.0%)	1/15 (6.7%)	5/15 (33.3%)	Hassan et al (2012)
Haploidentical	3/7 (42.9%)	2/7 (28.6%)	2/7 (28.6%)	Hassan et al (2012) [using 2000-2009 cohort]

*Section 5.2.6.3, p81*

The ERG notes that ██████ in the Named Patient Programme required rescue therapy, and inclusion of these data would give a rescue transplant rate of ██████ and a corresponding successful engraftment rate of ██████.

Figure 6. p123

Figure 1: Two way sensitivity analysis for initial procedure survival rates showing ICER for Strimvelis compared to Haplo

	Strimvelis Survival ↓		Haplo Survival →		ERG base case*					
	1.00	0.96	0.92	0.88	0.84	0.80	0.76	0.72	0.714	
1.00	Dominant	Dominant	Dominant	£1,413	£6,707	£10,715	£13,856	£16,383	<b>£16,704</b>	
0.98	Dominant	Dominant	Dominant	Dominant	£5,479	£9,942	£13,376	£16,101	£16,445	
0.96	Dominant	Dominant	Dominant	Dominant	£4,024	£9,046	£12,830	£15,784	£16,153	
0.94	Dominant	Dominant	Dominant	Dominant	£2,273	£7,996	£12,202	£15,424	£15,824	
0.92	Dominant	Dominant	Dominant	Dominant	£124	£6,747	£11,473	£15,014	£15,449	
0.90	Dominant	Dominant	Dominant	Dominant	Dominant	£5,238	£10,615	£14,542	£15,018	
0.88	£1,218,861	Dominant	Dominant	Dominant	Dominant	Dominant	£3,378	£9,592	£13,991	
0.86	£271,284	Dominant	Dominant	Dominant	Dominant	Dominant	£1,027	£8,349	£13,342	
0.84	£160,825	£595,462	Dominant	Dominant	Dominant	Dominant	Dominant	£6,810	£12,565	
0.82	£118,051	£210,925	Dominant	Dominant	Dominant	Dominant	Dominant	£4,852	£11,617	

